These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 32070164)

  • 1. Use of intra-procedural fusion imaging combining contrast-enhanced ultrasound using a perflubutane-based contrast agent and auto sweep three-dimensional ultrasound for guiding radiofrequency ablation and evaluating its efficacy in patients with hepatocellular carcinoma.
    Sanga K; Numata K; Nihonmatsu H; Ogushi K; Fukuda H; Chuma M; Hashimoto H; Koizumi N; Maeda S
    Int J Hyperthermia; 2020; 37(1):202-211. PubMed ID: 32070164
    [No Abstract]   [Full Text] [Related]  

  • 2. Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography.
    Nishigori S; Numata K; Irie K; Fukuda H; Chuma M; Maeda S
    J Med Ultrason (2001); 2018 Jul; 45(3):405-415. PubMed ID: 29362966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion imaging of contrast-enhanced ultrasound and contrast-enhanced CT or MRI before radiofrequency ablation for liver cancers.
    Bo XW; Xu HX; Wang D; Guo LH; Sun LP; Li XL; Zhao CK; He YP; Liu BJ; Li DD; Zhang K
    Br J Radiol; 2016 Nov; 89(1067):20160379. PubMed ID: 27626506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ablative safety margin depicted by fusion imaging with post-treatment contrast-enhanced ultrasound and pre-treatment CECT/CEMRI after radiofrequency ablation for liver cancers.
    Bo XW; Xu HX; Guo LH; Sun LP; Li XL; Zhao CK; He YP; Liu BJ; Li DD; Zhang K; Wang D
    Br J Radiol; 2017 Oct; 90(1078):20170063. PubMed ID: 28749166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate evaluation and guidance of liver cancer thermal ablation by three-dimensional ultrasound/contrast-enhanced ultrasound fusion imaging.
    Xu EJ; Lv SM; Li K; Long YL; Zeng QJ; Su ZZ; Zheng RQ
    Int J Hyperthermia; 2018 Sep; 34(6):870-876. PubMed ID: 28847188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of fusion imaging combining contrast-enhanced ultrasonography with a perflubutane-based contrast agent and contrast-enhanced computed tomography for the evaluation of percutaneous radiofrequency ablation of hypervascular hepatocellular carcinoma.
    Numata K; Fukuda H; Morimoto M; Kondo M; Nozaki A; Oshima T; Okada M; Takebayashi S; Maeda S; Tanaka K
    Eur J Radiol; 2012 Oct; 81(10):2746-53. PubMed ID: 22197088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D fusion is superior to 2D point-to-point contrast-enhanced US to evaluate the ablative margin after RFA for hepatocellular carcinoma.
    Long H; Zhou X; Zhang X; Ye J; Huang T; Cong L; Xie X; Huang G
    Eur Radiol; 2024 Feb; 34(2):1247-1257. PubMed ID: 37572191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Contrast-enhanced Ultrasound in Guiding Radiofrequency Ablation of Hepatocellular Carcinoma: A Retrospective Study.
    Chan AK; Hegarty C; Klass D; Yoshida E; Chung S; Liu DM; Ho SG; Harris AC
    Can Assoc Radiol J; 2015 May; 66(2):171-8. PubMed ID: 25637354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiofrequency ablation for hepatocellular carcinoma: utility of conventional ultrasound and contrast-enhanced ultrasound in guiding and assessing early therapeutic response and short-term follow-up results.
    Du J; Li HL; Zhai B; Chang S; Li FH
    Ultrasound Med Biol; 2015 Sep; 41(9):2400-11. PubMed ID: 26055968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous Radiofrequency Ablation of Small (1-2 cm) Hepatocellular Carcinomas Inconspicuous on B-Mode Ultrasonographic Imaging: Usefulness of Combined Fusion Imaging with MRI and Contrast-Enhanced Ultrasonography.
    Lee MW; Lim HK; Rhim H; Cha DI; Kang TW; Song KD; Min JH; Gwak GY; Kim S; Lu DSK
    Can J Gastroenterol Hepatol; 2018; 2018():7926923. PubMed ID: 30013957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of contrast-enhanced ultrasound in planning treatment protocols for hepatocellular carcinoma before radiofrequency ablation.
    Chen MH; Yang W; Yan K; Dai Y; Wu W; Fan ZH; Callstrom MR; Charboneau JW
    Clin Radiol; 2007 Aug; 62(8):752-60. PubMed ID: 17604763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fusion imaging-guided radiofrequency ablation for residual hepatocellular carcinoma invisible on ultrasound after transcatheter arterial chemoembolization.
    Gu JH; Zhao QY; He C; Ye ZD; Xu M; Jiang TA
    Int J Hyperthermia; 2021; 38(1):1092-1098. PubMed ID: 34296656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraprocedural contrast-enhanced ultrasound-CT/MR fusion imaging assessment in HCC thermal ablation to reduce local tumor progression: compared with routine contrast-enhanced ultrasound.
    Ju JX; Zeng QJ; Xu EJ; He XQ; Tan L; Huang QN; Li K; Zheng RQ
    Int J Hyperthermia; 2019; 36(1):785-793. PubMed ID: 31431086
    [No Abstract]   [Full Text] [Related]  

  • 14. Contrast-enhanced ultrasound-guided radiofrequency ablation in inconspicuous hepatocellular carcinoma on B-mode ultrasound.
    Kim EJ; Kim YS; Shin SK; Kwon OS; Choi DJ; Kim JH
    Turk J Gastroenterol; 2017 Nov; 28(6):446-452. PubMed ID: 29086712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast-enhanced ultrasound improves real-time imaging of ablation region during radiofrequency ablation: preliminary results.
    Wiggermann P; Zuber-Jerger I; Zausig Y; Loss M; Scherer MN; Schreyer AG; Stroszczynski C; Jung EM
    Clin Hemorheol Microcirc; 2011; 49(1-4):43-54. PubMed ID: 22214677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiofrequency ablation of very-early-stage hepatocellular carcinoma inconspicuous on fusion imaging with B-mode US: value of fusion imaging with contrast-enhanced US.
    Min JH; Lim HK; Lim S; Kang TW; Song KD; Choi SY; Rhim H; Lee MW
    Clin Mol Hepatol; 2014 Mar; 20(1):61-70. PubMed ID: 24757660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination guidance of contrast-enhanced US and fusion imaging in radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on contrast-enhanced US/fusion imaging.
    Minami T; Minami Y; Chishina H; Arizumi T; Takita M; Kitai S; Yada N; Inoue T; Hagiwara S; Ueshima K; Nishida N; Kudo M
    Oncology; 2014; 87 Suppl 1():55-62. PubMed ID: 25427734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multi-center study in China.
    Lu MD; Yu XL; Li AH; Jiang TA; Chen MH; Zhao BZ; Zhou XD; Wang JR
    Ultrasound Med Biol; 2007 Nov; 33(11):1736-49. PubMed ID: 17629608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment evaluation with contrast-enhanced ultrasonography for percutaneous radiofrequency ablation of hepatocellular carcinomas with poor conspicuity on conventional ultrasonography.
    Kim AY; Lee MW; Rhim H; Cha DI; Choi D; Kim YS; Lim HK; Cho SW
    Korean J Radiol; 2013; 14(5):754-63. PubMed ID: 24043968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of hepatocellular carcinoma tumor vascularity using contrast-enhanced ultrasonography as a predictor for local recurrence following radiofrequency ablation.
    Ishii T; Numata K; Hao Y; Doba N; Hara K; Kondo M; Tanaka K; Maeda S
    Eur J Radiol; 2017 Apr; 89():234-241. PubMed ID: 28034569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.